Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000919574-25-001031
Filing Date
2025-02-12
Accepted
2025-02-12 18:40:08
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 11651
2 d11597485_ex99-a.htm EX-99 5375
3 dd11597485_ex99-b.htm EX-99 871
  Complete submission text file 0000919574-25-001031.txt   19851
Mailing Address 5 RADNOR CORPORATE CENTER SUITE 500 100 MATSONFORD RD RADNOR PA 19087
Business Address 5 RADNOR CORPORATE CENTER SUITE 500 100 MATSONFORD RD RADNOR PA 19087 484-801-4670
MARINUS PHARMACEUTICALS, INC. (Subject) CIK: 0001267813 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88269 | Film No.: 25616519
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 3000 Sand Hill Road BUILDING 4-SUITE 250 Menlo Park CA 94025
Business Address 3000 Sand Hill Road BUILDING 4-SUITE 250 Menlo Park CA 94025 650.681.8428
Sofinnova Investments, Inc. (Filed by) CIK: 0001631134 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13G/A